Literature DB >> 6752

Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system.

G Bartholini.   

Abstract

In gallamine-immobilized cats, the caudate nucleus and the nucleus accumbens septi were perfused by means of a push-pull cannula and dopamine was measured in the perfusate. Chlorpromazine (10 mg kg(-1)) and clozapine (20 mg kg(-1)), administered intravenously, enhanced the release of dopamine. The effect of chlorpromazine was similar in both regions whereas that of clozapine was more pronounced in the nucleus accumbens than in the caudate nucleus. Furthermore, in the rat, sulpiride, clozapine and thioridazine increased the homovanillic acid concentration in striatum and limbic system to a similar extent. However, following probenecid administration, the net effect of these drugs on homovanillic acid accumulation was more marked in the limbic system than in the striatum whereas haolperidol and chlorpromazine had a similar effect in the two regions. It is concluded that, in contrast to haloperidol and chlorpromazine, sulpiride, clozapine and thioridazine may preferentially affect the limbic dopaminergic transmission. This possibly accounts for the fact that sulpiride, clozapine and thioridazine display an antipsychotic action and yet cause less extrapyramidal side effects than haloperidol and chlorpromazine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6752     DOI: 10.1111/j.2042-7158.1976.tb04648.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  36 in total

1.  Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.

Authors:  J Gerlach; H Simmelsgaard
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

2.  Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists.

Authors:  C A Altar; W C Boyar; A Wasley; S C Gerhardt; J M Liebman; P L Wood
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

3.  Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study.

Authors:  J A Stamford; Z L Kruk; J Millar
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

4.  Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action.

Authors:  T Ljungberg; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1978-04-11       Impact factor: 4.530

Review 5.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice.

Authors:  M Vasse; P Protais; J Costentin; J C Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

7.  Bromperidol, a new butyrophenone neuroleptic: a review.

Authors:  B Dubinsky; J L McGuire; C J Niemegeers; P A Janssen; H S Weintraub; B E McKenzie
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain.

Authors:  P Hertel; G G Nomikos; M Iurlo; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 9.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

10.  Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.

Authors:  C Köhler; L Haglund; S O Ogren; T Angeby
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.